Clinical Trials on Corneal Blindess in Japan

Total 25 results

Topcon Corporation

Completed

Clinical Study of the Topcon Pachymeter TRK-3 to Evaluate Agreement and Precision

Corneal Thickness

Japan
Santen Pharmaceutical Co., Ltd.

Completed

Study of DE-105 Ophthalmic Solution in Patients With Persistent Corneal Epithelial Defect

Persistent Corneal Epithelial Defect

Japan
Alcon Research

Completed

Clinical Investigation of an AcrySof IQ PanOptix Toric Intraocular Lens

Corneal Astigmatism | Aphakia

Japan
Kagawa University

Unknown

Combined 25-gauge Vitrectomy and Cataract Surgery With Toric Intraocular Lens With Idiopathic Epiretinal Membrane.

Cataract | Corneal Astigmatism | Epiretinal Membrane

Japan
Santen Pharmaceutical Co., Ltd.

Completed

Phase III Confirmatory Study of DE-089 Ophthalmic Solution in Patients With Dry Eye

Dry Eye

Japan
Santen Pharmaceutical Co., Ltd.

Completed

Late Phase II Confirmatory Study of DE-089 Ophthalmic Solution in Patients With Dry Eye

Dry Eye

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

Dose-response Study of OPC-12759 Ophthalmic Suspension

Dry Eye Syndromes

Japan
Meiji University of Oriental Medicine
Kyoto Prefectural University of Medicine

Unknown

The Evaluation of Thiol Redox Status in Conjunctiva of Dry Eye Patients

Dry Eye Disease

Japan
Alcon Research

Completed

Clinical Pharmacological Study of AL-43546 Ophthalmic Product in Subjects With Shortened Tear Film Break Up Time

Dry Eye Disease

Japan
Asia Cornea Society
Singapore Clinical Research Institute

Unknown

The Asia Cornea Society Infectious Keratitis Study (ACSIKS)

Corneal Ulcer

Singapore, China, India, Japan, Korea, Republic of, Philippines, Taiwan, Thailand
Otsuka Pharmaceutical Co., Ltd.

Completed

Confirmatory Study of OPC-12759 Ophthalmic Suspension

Dry Eye Syndromes

Japan
Astellas Pharma Inc

Completed

Phase III Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Patients With Vernal Keratoconjunctivitis

Keratoconjunctivitis | Conjunctivitis

Japan
Astellas Pharma Inc

Completed

Phase III, Long-Term, Open-Label, Extension Study of 0.1% Tacrolimus(FK506) Ophthalmic Suspension in Patients With Vernal Keratoconjunctivitis

Keratoconjunctivitis | Conjunctivitis

Japan
Kissei Pharmaceutical Co., Ltd.

Completed

A Parallel Group Phase II Study of KCT-0809 in Patients With Dry Eye Syndromes

Dry Eye Syndromes

Japan
Kissei Pharmaceutical Co., Ltd.

Completed

A Late Phase II Study of KCT-0809 in Patients With Dry Eye Syndromes

Dry Eye Syndromes

Japan
Kissei Pharmaceutical Co., Ltd.

Completed

A Phase II Study of KCT-0809 in Patients With Dry Eye Syndrome

Dry Eye Syndromes

Japan
Kissei Pharmaceutical Co., Ltd.

Completed

A Study of KCT-0809 in Patients With Dry Eye Syndromes

Dry Eye Syndromes

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

Confirmatory Study of OPC-12759 Ophthalmic Solution

Dry Eye

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

Long Term Administration Study of OPC-12759 Ophthalmic Suspension

Dry Eye Syndromes

Japan
Otsuka Pharmaceutical Co., Ltd.

Completed

Late Phase 2 Study of OPC-12759 Ophthalmic Suspension

Dry Eye Syndromes

Japan
Kissei Pharmaceutical Co., Ltd.

Completed

Phase 2 Study of KLS-0611 in Patients With Dry Eye Syndromes

Dry Eye Syndromes

Japan
Kissei Pharmaceutical Co., Ltd.

Terminated

An Extension Study of KCT-0809 in Dry Eye Patients With Sjögren's Syndrome

Dry Eye With Sjögren's Syndrome

Japan
Kissei Pharmaceutical Co., Ltd.

Completed

A Long-term Study of KCT-0809 in Dry Eye Patients With Sjögren's Syndrome

Dry Eye With Sjögren's Syndrome

Japan
Kissei Pharmaceutical Co., Ltd.

Completed

A Phase III Study of KCT-0809 in Dry Eye Patients With Sjögren's Syndrome

Dry Eye With Sjögren's Syndrome

Japan
Pfizer

Completed

A Phase II, Dose Ranging Study Of CP-690,550 Eye Drops In Patients With Dry Eye Disease

Dry Eye Syndromes

Korea, Republic of, Japan

Clinical Trials on Corneal Blindess in Japan

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bosnia & Herzegovina

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations